Comparative Pharmacology
Head-to-head clinical analysis: DEXTROSE 5 SODIUM CHLORIDE 0 2 AND POTASSIUM CHLORIDE 5MEQ K versus MAGNESIUM SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXTROSE 5 SODIUM CHLORIDE 0 2 AND POTASSIUM CHLORIDE 5MEQ K versus MAGNESIUM SULFATE.
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K) vs MAGNESIUM SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dextrose 5% provides free water and calories, promoting glucose metabolism and cellular energy production; sodium chloride 0.2% provides sodium and chloride ions for maintenance of extracellular fluid volume and osmolality; potassium chloride provides potassium ions essential for nerve conduction, muscle contraction, and acid-base balance.
Magnesium sulfate acts as a physiological calcium channel blocker. It inhibits calcium influx into presynaptic nerve terminals, reducing acetylcholine release at the neuromuscular junction and decreasing muscle contraction. It also antagonizes NMDA receptors and stabilizes neuronal membranes.
Intravenous infusion, administered at a rate of 100-125 mL/hour in adults, adjusting based on fluid and electrolyte status. Typically provides 5 g dextrose, 34 mEq sodium, 34 mEq chloride, and 5 mEq potassium per liter.
IV: Loading dose 4-6 g over 20-30 minutes, followed by maintenance infusion 1-2 g/hour for seizure prophylaxis in severe preeclampsia/eclampsia. IM: 4-8 g deep IM initially, then 4 g every 4 hours as needed.
None Documented
None Documented
Dextrose: <1 min (rapid cellular uptake); potassium: 6-8 h (redistribution half-life in hyperkalemia). Clinically, potassium's elimination half-life is 12-24 h in normal renal function.
Terminal elimination half-life approximately 4-6 hours in patients with normal renal function; prolonged to 12-24 hours or more in renal impairment, necessitating dose adjustment
Renal: 100% (dextrose is metabolized to CO2 and water; sodium, chloride, and potassium are excreted renally).
Primarily renal (90-95% as unchanged drug); minor biliary/fecal (<5%)
Category A/B
Category C
Electrolyte
Electrolyte